Alzheimer Disease

Probiodrug AG Acquires Ingenium Pharmaceuticals AG to Form an Integrated Biopharmaceutical Company

Published in Healthcare Finance, Tax and Law Weekly, July 11th, 2007

Probiodrug AG (Probiodrug), a developer of small molecule inhibitors against inflammatory and neurodegenerative diseases, has acquired Ingenium Pharmaceuticals AG, a discovery and development company focused on inflammatory diseases, both companies announced today.

The combined entity has simultaneously closed a Series A financing round of Euro 20.6 million (US$ 27.6 million) to ensure the rapid development of the company's pipeline of compounds targeted to treat Alzheimer's disease and chronic inflammatory diseases. TVM Capital and HBM BioVentures (Cayman) Ltd. financed together with IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH (IBG), Sachsen LB Corporate Finance...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-07-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry